Abstract
Objective: it was to investigate the impact of the tyrosine kinase inhibitor Apatinib as an adjunct to 125I particle implantation therapy in thyroid cancer patients.
Methods: data from 130 cases of thyroid cancer patients were collected. Based on treatment methods, 62 cases were categorized into the control group (CG, 125I particle implantation therapy alone) and 68 cases into the experimental group (EG, 125I particle implantation therapy + Apatinib). Clinical efficacy, thyroid function indices, ultrasound imaging features, serum biomarkers, and adverse events were compared between groups.
Results: the objective response rate (82.26% vs. 73.33%) and disease control rate (91.94% vs. 80%) in EG were greatly superior to those in CG (P<0.05). Triiodothyronine and serum thyroxine were markedly lower, while thyroid-stimulating hormone levels were notably higher in EG versus CG (P<0.05). EG showed drastically reduced maximum lymph node diameter, lymph node number, and calcification points versus CG (P<0.05). Levels of thyroglobulin, thyroglobulin antibodies, and protein kinase B were substantially lower in EG than in CG (P<0.05). The incidence of adverse reactions was comparable between EG (12.9%) and CG (11.76%) (P>0.05).
Conclusion: Apatinib as an adjunct to 125I particle implantation therapy effectively suppresses thyroid function, reduces thyroid hormone levels, and holds great promise not only in enhancing treatment efficacy and suppressing thyroid cancer activity but also in demonstrating higher safety levels.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.